Thursday November 26 2009 | Biotechnology feed | All feeds

BioPortfolio Biotechnology Pharmaceutical Healthcare Medical Life Science Drug Discovery Disease

Raf Kinases

Download PDF containing detailed information.PDF Version

Image Results

Loading...

Recent Publications on Raf Kinases:

Pubmed Logo
Sprouty2 association with B-Raf is regulated by phosphorylation and kinase conformation.
Sprouty2 is a feedback regulator that controls the...
18th November, 2009
The Beatson Institute for Cancer Research, Glasgow, United Kingdom. Cancer Res. 2009 Sep 1;69(17):6773-81. Epub 2009 Aug 18.
DOI Direct Link
(-)-Epigallocatechin-3-gallate (EGCG) increases the viability of serum-starved A549 cells through its effect on Akt.
The effect of epigallocatechin gallate (EGCG) on cell survival was studied...
17th November, 2009
Department of Oral Pathology, Pusan National University, Yang San, South Am J Chin Med. 2009;37(4):723-34.
Identification of novel in vivo phosphorylation sites of the human proapoptotic protein BAD: pore-forming activity of BAD is regulated by phosphorylation.
BAD is a proapoptotic member of the Bcl-2 protein family that is regulated...
11th November, 2009
Institute for Medical Radiation and Cell Research, University of J Biol Chem. 2009 Oct 9;284(41):28004-20. Epub 2009 Aug 10.
DOI Direct Link
Can BAD pores be good? New insights from examining BAD as a target of RAF kinases.
The objective of this study was chromosomal analysis and measurement of...
10th November, 2009
Max-Planck-Institut fur Herz- und Lungenforschung, W.G. Adv Enzyme Regul. 2009 Nov 4.
DOI Direct Link
RGS14 is a multifunctional scaffold that integrates G protein and Ras/Raf MAPkinase signalling pathways.
MAPkinase signalling is essential for cell growth, differentiation and...
3rd November, 2009
Department of Pharmacology, Emory University School of Medicine, Atlanta, Cell Signal. 2009 Oct 27.
DOI Direct Link

View more research publications.

Press Releases About Raf Kinases:

BioPortfolio Logo
Bayer and Onyx Announce Nexavar Data Presentations at 60th American Association for the Study of Liver Diseases Annual Meeting 29th October, 2009 Onyx Pharmaceuticals, Inc.
-- Late Breaker #9 First-in-men Demonstration of Sorafenib Plus TACE for the Treatment of Advanced Hepatocellular Carcinoma (SOCRATES trial) -- Dr. Andreas Erhardt, Klinik fur
Bayer and Onyx Initiate Phase 3 Trial of Nexavar in Patients With Non-Responsive Thyroid Cancer 23rd October, 2009 Onyx Pharmaceuticals, Inc.
WAYNE, N.J. and EMERYVILLE, Calif., Oct. 23 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals, Inc. and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced the companies have begun
Results Reported for Exploratory Phase 2 Study of Nexavar in Combination With Chemotherapeutic Agent Paclitaxel for Treatment of Advanced Breast Cancer 30th September, 2009 Onyx Pharmaceuticals, Inc.
WAYNE, N.J. and EMERYVILLE, Calif., Sept. 30 /PRNewswire-FirstCall/ -- Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. (Nasdaq: ONXX) today announced results from a randomized, placebo
Sunesis Reports Financial Results for the Second Quarter 2009 29th July, 2009 Sunesis Pharmaceuticals, Inc.
-- On July 24, 2009, Sunesis applied to transfer the listing of its common stock from The NASDAQ Global Market to The NASDAQ Capital Market. The NASDAQ Capital Market is a
Debiopharm Group and Moffitt Cancer Center Sign Development and Commercialisation Agreement for Small Molecule Debio 0928 in Early Preclinical Development for Treatment of Solid Tumours 18th June, 2009 Debiopharm Group
LAUSANNE, Switzerland and TAMPA, Florida, June 18 /PRNewswire/ -- Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of

Raf Kinases Patents:

USPTO Logo
US Patent No.Title
7173136 3-Cyano-quinoline derivatives
7354945 2-oxadiazolechromone derivatives
7368542 Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
7371763 Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
7375105 Pyridine substituted furan derivatives as Raf kinase inhibitors

View more patents.

BioPortfolio Ltd. offers e-mail and postal lists for Raf Kinases scientists - we have details of around 28 individuals working on Raf Kinases .


This page has been viewed 290 times
Recent Search Terms used to find this page: us patents raf | raf kinases | XL281 | raf | .
Browse BioPortfolio's InDepth service - alphabetically: A B C D E F G H I J K L M N O P Q R S T U V W X Y Z or by Most Publications, recently searched for, or most viewed.

Search for Raf Kinases across BioPortfolio, or for Raf Kinases Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH. Thumbshots from Thumbshots.org

 

Nothing in this website should be used in place of personal medical advice from your own qualified medical practitioner.

All rights reserved. All other trademarks recognized.
Copyright 1997-2009 - BioPortfolio Limited.